Last reviewed · How we verify
Pravastatin and Cyclosporine
Pravastatin and Cyclosporine is a Small molecule drug developed by University of California, San Francisco. It is currently in Phase 1 development.
At a glance
| Generic name | Pravastatin and Cyclosporine |
|---|---|
| Sponsor | University of California, San Francisco |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Drug-Drug Interaction Study With Pravastatin and Cyclosporine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pravastatin and Cyclosporine CI brief — competitive landscape report
- Pravastatin and Cyclosporine updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Pravastatin and Cyclosporine
What is Pravastatin and Cyclosporine?
Pravastatin and Cyclosporine is a Small molecule drug developed by University of California, San Francisco.
Who makes Pravastatin and Cyclosporine?
Pravastatin and Cyclosporine is developed by University of California, San Francisco (see full University of California, San Francisco pipeline at /company/university-of-california-san-francisco).
What development phase is Pravastatin and Cyclosporine in?
Pravastatin and Cyclosporine is in Phase 1.